SG Americas Securities LLC Invests $531,000 in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

SG Americas Securities LLC acquired a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 63,844 shares of the company's stock, valued at approximately $531,000.

Other institutional investors also recently modified their holdings of the company. Hennessy Advisors Inc. bought a new stake in Amneal Pharmaceuticals during the second quarter valued at $8,818,000. Rubric Capital Management LP boosted its position in Amneal Pharmaceuticals by 12.4% during the second quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company's stock valued at $68,083,000 after acquiring an additional 1,179,830 shares during the last quarter. Acadian Asset Management LLC boosted its position in Amneal Pharmaceuticals by 701.8% during the second quarter. Acadian Asset Management LLC now owns 811,853 shares of the company's stock valued at $5,148,000 after acquiring an additional 710,598 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Amneal Pharmaceuticals by 17.6% during the second quarter. Dimensional Fund Advisors LP now owns 4,283,928 shares of the company's stock valued at $27,205,000 after acquiring an additional 641,405 shares during the last quarter. Finally, BlackBarn Capital Partners LP boosted its position in Amneal Pharmaceuticals by 41.5% during the second quarter. BlackBarn Capital Partners LP now owns 2,000,000 shares of the company's stock valued at $12,700,000 after acquiring an additional 586,703 shares during the last quarter. Institutional investors own 31.82% of the company's stock.

Amneal Pharmaceuticals Trading Down 1.2 %

Shares of AMRX traded down $0.11 on Wednesday, reaching $8.70. The company's stock had a trading volume of 824,572 shares, compared to its average volume of 1,441,240. Amneal Pharmaceuticals, Inc. has a twelve month low of $3.36 and a twelve month high of $8.95. The stock has a market capitalization of $2.69 billion, a PE ratio of -15.54 and a beta of 1.18. The firm has a fifty day moving average of $8.37 and a 200-day moving average of $7.21.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its earnings results on Friday, August 9th. The company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.04. Amneal Pharmaceuticals had a negative net margin of 6.72% and a positive return on equity of 1,235.03%. The company had revenue of $701.78 million for the quarter, compared to analyst estimates of $657.43 million. As a group, equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.52 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on AMRX. Truist Financial increased their price objective on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Wednesday, October 2nd. Barclays increased their price objective on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 13th. Finally, JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 price objective on the stock in a research report on Friday, September 6th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.40.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.